Central data monitoring in the multicentre randomised SafeBoosC-III trial – a pragmatic approach

Abstract Background Data monitoring of clinical trials is a tool aimed at reducing the risks of random errors (e.g. clerical errors) and systematic errors, which include misinterpretation, misunderstandings, and fabrication. Traditional ‘good clinical practice data monitoring’ with on-site monitors...

Full description

Bibliographic Details
Main Authors: Markus Harboe Olsen, Mathias Lühr Hansen, Sanam Safi, Janus Christian Jakobsen, Gorm Greisen, Christian Gluud, The SafeBoosC-III Trial Group
Format: Article
Language:English
Published: BMC 2021-07-01
Series:BMC Medical Research Methodology
Subjects:
Online Access:https://doi.org/10.1186/s12874-021-01344-4
id doaj-da3d05b8b2ab4e808c3fea013aa25e9f
record_format Article
spelling doaj-da3d05b8b2ab4e808c3fea013aa25e9f2021-08-01T11:43:48ZengBMCBMC Medical Research Methodology1471-22882021-07-0121111010.1186/s12874-021-01344-4Central data monitoring in the multicentre randomised SafeBoosC-III trial – a pragmatic approachMarkus Harboe Olsen0Mathias Lühr Hansen1Sanam Safi2Janus Christian Jakobsen3Gorm Greisen4Christian Gluud5The SafeBoosC-III Trial GroupCopenhagen Trial Unit, Centre for Clinical Intervention Research, The Capital Region, Copenhagen University Hospital - RigshospitaletDepartment of Neonatology, Juliane Marie Centre, Copenhagen University Hospital - RigshospitaletCopenhagen Trial Unit, Centre for Clinical Intervention Research, The Capital Region, Copenhagen University Hospital - RigshospitaletCopenhagen Trial Unit, Centre for Clinical Intervention Research, The Capital Region, Copenhagen University Hospital - RigshospitaletDepartment of Neonatology, Juliane Marie Centre, Copenhagen University Hospital - RigshospitaletCopenhagen Trial Unit, Centre for Clinical Intervention Research, The Capital Region, Copenhagen University Hospital - RigshospitaletAbstract Background Data monitoring of clinical trials is a tool aimed at reducing the risks of random errors (e.g. clerical errors) and systematic errors, which include misinterpretation, misunderstandings, and fabrication. Traditional ‘good clinical practice data monitoring’ with on-site monitors increases trial costs and is time consuming for the local investigators. This paper aims to outline our approach of time-effective central data monitoring for the SafeBoosC-III multicentre randomised clinical trial and present the results from the first three central data monitoring meetings. Methods The present approach to central data monitoring was implemented for the SafeBoosC-III trial, a large, pragmatic, multicentre, randomised clinical trial evaluating the benefits and harms of treatment based on cerebral oxygenation monitoring in preterm infants during the first days of life versus monitoring and treatment as usual. We aimed to optimise completeness and quality and to minimise deviations, thereby limiting random and systematic errors. We designed an automated report which was blinded to group allocation, to ease the work of data monitoring. The central data monitoring group first reviewed the data using summary plots only, and thereafter included the results of the multivariate Mahalanobis distance of each centre from the common mean. The decisions of the group were manually added to the reports for dissemination, information, correcting errors, preventing furture errors and documentation. Results The first three central monitoring meetings identified 156 entries of interest, decided upon contacting the local investigators for 146 of these, which resulted in correction of 53 entries. Multiple systematic errors and protocol violations were identified, one of these included 103/818 randomised participants. Accordingly, the electronic participant record form (ePRF) was improved to reduce ambiguity. Discussion We present a methodology for central data monitoring to optimise quality control and quality development. The initial results included identification of random errors in data entries leading to correction of the ePRF, systematic protocol violations, and potential protocol adherence issues. Central data monitoring may optimise concurrent data completeness and may help timely detection of data deviations due to misunderstandings or fabricated data.https://doi.org/10.1186/s12874-021-01344-4Central monitoringData qualityData deviationsMissing dataClinical trialsMahalanobis distance
collection DOAJ
language English
format Article
sources DOAJ
author Markus Harboe Olsen
Mathias Lühr Hansen
Sanam Safi
Janus Christian Jakobsen
Gorm Greisen
Christian Gluud
The SafeBoosC-III Trial Group
spellingShingle Markus Harboe Olsen
Mathias Lühr Hansen
Sanam Safi
Janus Christian Jakobsen
Gorm Greisen
Christian Gluud
The SafeBoosC-III Trial Group
Central data monitoring in the multicentre randomised SafeBoosC-III trial – a pragmatic approach
BMC Medical Research Methodology
Central monitoring
Data quality
Data deviations
Missing data
Clinical trials
Mahalanobis distance
author_facet Markus Harboe Olsen
Mathias Lühr Hansen
Sanam Safi
Janus Christian Jakobsen
Gorm Greisen
Christian Gluud
The SafeBoosC-III Trial Group
author_sort Markus Harboe Olsen
title Central data monitoring in the multicentre randomised SafeBoosC-III trial – a pragmatic approach
title_short Central data monitoring in the multicentre randomised SafeBoosC-III trial – a pragmatic approach
title_full Central data monitoring in the multicentre randomised SafeBoosC-III trial – a pragmatic approach
title_fullStr Central data monitoring in the multicentre randomised SafeBoosC-III trial – a pragmatic approach
title_full_unstemmed Central data monitoring in the multicentre randomised SafeBoosC-III trial – a pragmatic approach
title_sort central data monitoring in the multicentre randomised safeboosc-iii trial – a pragmatic approach
publisher BMC
series BMC Medical Research Methodology
issn 1471-2288
publishDate 2021-07-01
description Abstract Background Data monitoring of clinical trials is a tool aimed at reducing the risks of random errors (e.g. clerical errors) and systematic errors, which include misinterpretation, misunderstandings, and fabrication. Traditional ‘good clinical practice data monitoring’ with on-site monitors increases trial costs and is time consuming for the local investigators. This paper aims to outline our approach of time-effective central data monitoring for the SafeBoosC-III multicentre randomised clinical trial and present the results from the first three central data monitoring meetings. Methods The present approach to central data monitoring was implemented for the SafeBoosC-III trial, a large, pragmatic, multicentre, randomised clinical trial evaluating the benefits and harms of treatment based on cerebral oxygenation monitoring in preterm infants during the first days of life versus monitoring and treatment as usual. We aimed to optimise completeness and quality and to minimise deviations, thereby limiting random and systematic errors. We designed an automated report which was blinded to group allocation, to ease the work of data monitoring. The central data monitoring group first reviewed the data using summary plots only, and thereafter included the results of the multivariate Mahalanobis distance of each centre from the common mean. The decisions of the group were manually added to the reports for dissemination, information, correcting errors, preventing furture errors and documentation. Results The first three central monitoring meetings identified 156 entries of interest, decided upon contacting the local investigators for 146 of these, which resulted in correction of 53 entries. Multiple systematic errors and protocol violations were identified, one of these included 103/818 randomised participants. Accordingly, the electronic participant record form (ePRF) was improved to reduce ambiguity. Discussion We present a methodology for central data monitoring to optimise quality control and quality development. The initial results included identification of random errors in data entries leading to correction of the ePRF, systematic protocol violations, and potential protocol adherence issues. Central data monitoring may optimise concurrent data completeness and may help timely detection of data deviations due to misunderstandings or fabricated data.
topic Central monitoring
Data quality
Data deviations
Missing data
Clinical trials
Mahalanobis distance
url https://doi.org/10.1186/s12874-021-01344-4
work_keys_str_mv AT markusharboeolsen centraldatamonitoringinthemulticentrerandomisedsafeboosciiitrialapragmaticapproach
AT mathiasluhrhansen centraldatamonitoringinthemulticentrerandomisedsafeboosciiitrialapragmaticapproach
AT sanamsafi centraldatamonitoringinthemulticentrerandomisedsafeboosciiitrialapragmaticapproach
AT januschristianjakobsen centraldatamonitoringinthemulticentrerandomisedsafeboosciiitrialapragmaticapproach
AT gormgreisen centraldatamonitoringinthemulticentrerandomisedsafeboosciiitrialapragmaticapproach
AT christiangluud centraldatamonitoringinthemulticentrerandomisedsafeboosciiitrialapragmaticapproach
AT thesafeboosciiitrialgroup centraldatamonitoringinthemulticentrerandomisedsafeboosciiitrialapragmaticapproach
_version_ 1721245612141182976